

# Gunnar Tepe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2988815/publications.pdf>

Version: 2024-02-01

36  
papers

6,288  
citations

279487

23  
h-index

377514

34  
g-index

36  
all docs

36  
docs citations

36  
times ranked

4738  
citing authors

#	ARTICLE	IF	CITATIONS
1	Orbital Atherectomy Prior to Drug-Coated Balloon Angioplasty in Calcified Infrapopliteal Lesions: A Randomized, Multicenter Pilot Study. <i>Journal of Endovascular Therapy</i> , 2022, 29, 874-884.	0.8	9
2	Stents With Torsional Strength for Superficial Femoral Artery Disease: The Prospective Q3-Registry. <i>Journal of Endovascular Therapy</i> , 2022, , 152660282110677.	0.8	1
3	Sex-Related Outcomes Following Drug Balloon Angioplasty in Patients from the BIOLUX P-III Registry: A Subgroup Analysis. <i>CardioVascular and Interventional Radiology</i> , 2022, , 1.	0.9	0
4	Intravascular Lithotripsy for Peripheral Artery Calcification: Mid-term Outcomes From the Randomized Disrupt PAD III Trial. , 2022, 1, 100341.		15
5	Paclitaxel-Coated Balloon Angioplasty for the Treatment of Infringuinal Arteries: 24-Month Outcomes in the Full Cohort of BIOLUX P-III Global Registry. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 207-217.	0.9	13
6	BIOLUX P-III Passeo-18ÂLux All-Comers Registry: 24-Month Results in Below-the-Knee Arteries. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 10-18.	0.9	5
7	Intravascular Lithotripsy for Peripheral Artery Calcification. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1352-1361.	1.1	66
8	Twenty-Four-Month Outcomes of Drug-Coated Balloon in Diabetic Patients in the BIOLUX P-III Registry: A Subgroup Analysis. <i>Annals of Vascular Surgery</i> , 2021, 75, 237-252.	0.4	3
9	Real-World Experience With a Paclitaxel-Coated Balloon in Critical Limb Ischemia. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2289-2299.	1.1	12
10	Intravascular Lithotripsy for Treatment of Calcified Lower Extremity Arterial Stenosis: Initial Analysis of the Disrupt PAD III Study. <i>Journal of Endovascular Therapy</i> , 2020, 27, 473-480.	0.8	67
11	Three-Year Sustained Clinical Efficacy of Drug-Coated Balloon Angioplasty in a Real-World Femoropopliteal Cohort. <i>Journal of Endovascular Therapy</i> , 2020, 27, 693-705.	0.8	34
12	Paclitaxel-Coated Balloon vs Uncoated Balloon Angioplasty for Treatment of In-Stent Restenosis in the Superficial Femoral and Popliteal Arteries: The COPA CABANA Trial. <i>Journal of Endovascular Therapy</i> , 2020, 27, 276-286.	0.8	17
13	Paclitaxel-Coated Balloon for the Treatment of Infringuinal Disease: 12-Month Outcomes in the All-Comers Cohort of BIOLUX P-III Global Registry. <i>Journal of Endovascular Therapy</i> , 2020, 27, 304-315.	0.8	12
14	Paclitaxel and Mortality: The Dose Argument Is Critical. <i>Journal of Endovascular Therapy</i> , 2019, 26, 467-470.	0.8	24
15	Long-Term Clinical Effectiveness of a Drug-Coated Balloon for the Treatment of Femoropopliteal Lesions. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007702.	1.4	120
16	Mortality Not Correlated With PaclitaxelÂExposure. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2550-2563.	1.2	195
17	Primary outcomes and mechanism of action of intravascular lithotripsy in calcified, femoropopliteal lesions: Results of Disrupt PAD II. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 335-342.	0.7	120
18	Drug-Coated Balloon Treatment of Femoropopliteal Lesions for Patients With Intermittent Claudication and Ischemic Rest Pain. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007730.	1.4	10

#	ARTICLE	IF	CITATIONS
19	Treatment Effect of Drug-Coated Balloons Is Durable to 3 Years in the Femoropopliteal Arteries. Circulation: Cardiovascular Interventions, 2018, 11, e005891.	1.4	166
20	Two-Year Clinical Outcomes of the CONSEQUENT Trial: Can Femoropopliteal Lesions be Treated with Sustainable Clinical Results that are Economically Sound?. CardioVascular and Interventional Radiology, 2018, 41, 1008-1014.	0.9	43
21	2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). European Heart Journal, 2018, 39, 763-816.	1.0	2,305
22	Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease. Circulation: Cardiovascular Interventions, 2018, 11, e005654.	1.4	51
23	Drug-Coated Balloon Treatment of Femoropopliteal Lesions for Patients With Intermittent Claudication and Ischemic Rest Pain. JACC: Cardiovascular Interventions, 2018, 11, 945-953.	1.1	71
24	Directional Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis and Maintain Vessel Patency. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	180
25	Angiographic and Clinical Outcomes After Treatment of Femoro-Popliteal Lesions with a Novel Paclitaxel-Matrix-Coated Balloon Catheter. CardioVascular and Interventional Radiology, 2017, 40, 1535-1544.	0.9	42
26	Real-world experience with a Paclitaxel-Coated Balloon for the treatment of atherosclerotic infrainguinal arteries: 12-month interim results of the BIOLUX P-III registry first year of enrolment. Jornal Vascular Brasileiro, 2017, 16, 276-284.	0.1	9
27	Drug-coated balloon treatment for lower extremity vascular disease intervention: an international positioning document. European Heart Journal, 2016, 37, 1096-1103.	1.0	73
28	Durability of Treatment Effect Using a Drug-Coated Balloon for Femoropopliteal Lesions. Journal of the American College of Cardiology, 2015, 66, 2329-2338.	1.2	325
29	Drug-Coated Balloon Versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease. Circulation, 2015, 131, 495-502.	1.6	554
30	Angioplasty of Femoral-Popliteal Arteries With Drug-Coated Balloons. JACC: Cardiovascular Interventions, 2015, 8, 102-108.	1.1	230
31	Paclitaxel-Releasing Balloon in Femoropopliteal Lesions Using a BTHC Excipient. Journal of Endovascular Therapy, 2015, 22, 14-21.	0.8	134
32	Drug-Eluting Balloon Therapy for Femoropopliteal Occlusive Disease. Journal of Endovascular Therapy, 2015, 22, 727-733.	0.8	82
33	Treatment of Femoropopliteal In-Stent Restenosis With Paclitaxel-Eluting Stents. JACC: Cardiovascular Interventions, 2013, 6, 274-281.	1.1	109
34	Sustained Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Lesions. Journal of the American College of Cardiology, 2013, 61, 2417-2427.	1.2	307
35	Sirolimus-Eluting Stents for Treatment of Infrapopliteal Arteries Reduce Clinical Event Rate Compared to Bare-Metal Stents. Journal of the American College of Cardiology, 2012, 60, 587-591.	1.2	152
36	Local Delivery of Paclitaxel to Inhibit Restenosis during Angioplasty of the Leg. New England Journal of Medicine, 2008, 358, 689-699.	13.9	732